Huadong has been granted exclusive rights in Greater China to develop and commercialize MC2’s drug, Wynzora Cream, for the treatment of plaque psoriasis.
AbbVie receives approval from the US FDA for its newest psoriasis drug, Skyrizi, which looks set to recoup some of Humira’s revenue when it loses patent protection.